Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Humacyte Inc (HUMA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Humacyte's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.990 +0.090    +2.31%
26/04 - Closed. Currency in USD ( Disclaimer )
After Hours
4.000
+0.010
+0.25%
19:37:09 - Real-time Data
  • Volume: 685,852
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 3.850 - 4.010
Type:  Equity
Market:  United States
Humacyte 3.990 +0.090 +2.31%

Humacyte Inc Company Profile

 
Get an in-depth profile of Humacyte Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

164

Equity Type

ORD

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Contact Information

Address 2525 East North Carolina Highway 54
Durham, 27713
United States
Phone 919 313 9633
Fax -

Top Executives

Name Age Since Title
Terrance L. Carlson 67 2020 Independent Director
Rajiv Sarman Shukla 46 2020 Chairman of the Board & CEO
Brian Clanton Robertson 50 2020 Independent Director
Bruce A. Springer 51 2020 Independent Director
Yili Xie 50 2020 Independent Director
Kathleen G. Sebelius 75 2015 Independent Chairman of the Board
Brady William Dougan 64 2005 Director
Max N. Wallace 71 2005 Independent Director
Laura E. Niklason 60 2004 Founder, President, CEO & Director
Gordon M. Binder 85 2021 Independent Director
Emery N. Brown 65 2021 Independent Director
Todd M. Pope 58 - Independent Director
Rajiv Sarman Shukla 48 2021 Director
Michael T. Constantino 60 - Independent Director
Diane Seimetz 53 2022 Independent Director
C. Bruce Green - 2022 Independent Director
Susan R. Windham-Bannister 72 2021 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HUMA Comments

Write your thoughts about Humacyte Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email